John Sheridan - Tandem Diabetes COO and Executive VP
| TNDM Stock | USD 22.14 0.39 1.79% |
COO
Mr. John F. Sheridan is appointed as President, Chief Executive Officer, Director of Tandem Diabetes Care, Inc., Mr. Sheridan has served as our President and Chief Executive Officer since March 2019 and is our principal executive officer. Prior to that, Mr. Sheridan served as our Executive Vice President and Chief Operating Officer since April 2013. Prior to joining our Company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporationrationration, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. . From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporationrationration, a medical imaging company since 2019.
| Age | 70 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 12400 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 366 6900 |
| Web | https://www.tandemdiabetes.com |
John Sheridan Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Sheridan against Tandem Diabetes stock is an integral part of due diligence when investing in Tandem Diabetes. John Sheridan insider activity provides valuable insight into whether Tandem Diabetes is net buyers or sellers over its current business cycle. Note, Tandem Diabetes insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tandem Diabetes'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Sheridan over two months ago Disposition of 2773 shares by John Sheridan of Tandem Diabetes at 27.34 subject to Rule 16b-3 | ||
John Sheridan over six months ago Disposition of 325 shares by John Sheridan of Tandem Diabetes at 24.29 subject to Rule 16b-3 |
Tandem Diabetes Management Efficiency
The company has return on total asset (ROA) of (0.0645) % which means that it has lost $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of March 2025, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Tandem Diabetes' Total Assets are very stable compared to the past year. As of the 1st of March 2025, Non Current Assets Total is likely to grow to about 255.3 M, while Intangible Assets are likely to drop about 878.8 K.Similar Executives
| Found 2 records | COO Age | ||
| Jacob Leach | DexCom Inc | 47 | |
| Philip Ebeling | Inspire Medical Systems | 53 | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0645 |
Tandem Diabetes Care Leadership Team
Elected by the shareholders, the Tandem Diabetes' board of directors comprises two types of representatives: Tandem Diabetes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tandem. The board's role is to monitor Tandem Diabetes' management team and ensure that shareholders' interests are well served. Tandem Diabetes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tandem Diabetes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Hansen, Chief Commercial Officer, Executive Vice President | ||
| Tom Fox, Chief Officer | ||
| Susan Morrison, Chief Admin. Officer | ||
| Mark Novara, Executive Officer | ||
| Ross Sylvia, VP Marketing | ||
| David Esq, Transitional Advisor | ||
| Jordan MD, Chief Officer | ||
| Libba Sapitsky, Senior Care | ||
| Shannon JD, Chief VP | ||
| JeanClaude Kyrillos, Executive COO | ||
| Leigh Vosseller, Senior Vice President - Finance | ||
| Rick Carpenter, Chief Officer | ||
| John Sheridan, COO and Executive VP | ||
| Elizabeth Gasser, Executive Officer | ||
| Shannon Hansen, Privacy Legal |
Tandem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tandem Diabetes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0645 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 66.47 M | ||||
| Shares Owned By Insiders | 1.05 % | ||||
| Shares Owned By Institutions | 98.95 % | ||||
| Number Of Shares Shorted | 7.08 M | ||||
| Price To Earning | 494.25 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 0.436 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.